News & Updates

Stay informed with the latest developments in global research and academia. Our News and Updates section provides timely articles on breakthrough studies, funding announcements, and significant achievements from our academic community. From cutting-edge discoveries to policy changes affecting research, we deliver insights that keep you ahead in your field.

Engage with expert commentary, follow key trends, and discover opportunities that can shape the future of your work. Stay connected, stay current, and leverage the knowledge shared by leaders in research and academia worldwide.

University of Manchester: AI study reveals England’s productivity divide is far more complex than North-South

Researchers at The University of Manchester have used artificial intelligence to uncover a complex picture behind England’s long-running productivity puzzle, challenging the idea that the country’s economic performance can be explained by a simple North-South divide. In a major study published in the Spatial Economic Analysis journal, Professor Cecilia Wong and Dr Helen Zheng applied ‘GeoAI’ techniques - combining geography and artificial intelligence - to analyse how product

Apr 1

University of Manchester: UK cancer scientists uncover genetic clues as to what drives tumour growth

A team of scientists from Manchester and London have, for the first time, decoded the full range of mutations that drive tumour growth, which could pave the way for a new era in precision medicine, offering more effective treatments for thousands of people with cancer. A team of cancer genomics* scientists from The University of Manchester and The Institute of Cancer Research, London, forensically examined the genetic make-up of tumours in 16 different cancers. Their findings

Mar 30

University of Bristol: Researchers identify the most common recessive neurodevelopmental disorder ever discovered

The condition is caused by changes in a small noncoding gene called RNU2-2. It is estimated to affect thousands of individuals and accounts for about 10% of all recessive NDD cases with a known genetic cause. This discovery was first made by researchers from Icahn School of Medicine at Mount Sinai in New York in collaboration with colleagues from Stanford University and the University of Bristol. Clinical and scientific collaborators from other institutions in the UK, the Net

Mar 30

University of Cambridge: New computer chip material inspired by the human brain could slash AI energy use

The researchers, led by the University of Cambridge, developed a form of hafnium oxide that acts as a highly stable, low‑energy ‘memristor’ — a component designed to mimic the efficient way neurons are connected in the brain. The results are reported in the journal Science Advances. Current AI systems rely on conventional computer chips that shuttle data back and forth between memory and processing units. This constant movement consumes large amounts of electricity, and globa

Mar 25

Harvard University: Study suggests healing skin without scarring may be possible

Researchers unblock embryonic regrowth mechanism that shuts down after birth in mice Veasey Conway/Harvard Staff Photographer New findings by Harvard stem cell biologists suggest it may be possible in the future to regrow wounded skin without scarring. Read more

Mar 25

University of Oxford: New study finds that stored sperm deteriorates across the animal kingdom

Current World Health Organization (WHO) guidelines typically recommend 2–7 days of abstinence before taking semen samples or assisted reproduction. However, a new study published today and led by Oxford University researchers suggests that regular ejaculation – whether through sexual activity or... Read more

Mar 25

Imperial College London: Global waste to hit nearly 4 billion tonnes a year by 2050, World Bank Group report warns

Experts from Imperial, working independently through Imperial Consultants, have helped deliver a major new global analysis of rising waste, climate emissions and failures in basic rubbish collection. The world is on track to generate 3.86 billion tonnes of municipal solid waste a year by 2050, up from 2.56 billion tonnes in 2022, according to What a Waste 3.0, a new report from the World Bank Group. Drawing on data from 217 countries and economies, and 262 cities, the report

Mar 25

University of Manchester: Masked T‑cell engagers: cancer immunotherapies for the future?

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own immune arsenal to fight cancer. In the trial, which is still in progress and has not yet undergone peer-review, patients with advanced prostate cancer who had failed to respond to other treatments were given VIR-5500. Remarkably, initial findings showed that in the patients who r

Mar 25

Massachusetts Institute of Technology: Why solid-state batteries keep short-circuiting

Batteries that use solid metal as their charge-carrying electrolyte could potentially be a safer and far more energy-dense alternative to lithium-ion batteries. However, these solid-state batteries have been plagued by the formation of metallic cracks called dendrites that cause them to short circuit. The problem has so far prevented such batteries from becoming a major player in energy storage. But now, research from MIT could finally help engineers find a way to get past th

Mar 25

Oxford: Solved: New analysis of Apollo Moon samples finally settles debate about the Moon's magnetic field

Researchers from the Department of Earth Sciences, University of Oxford, have resolved a long-standing debate about the strength of the Moon’s magnetic field. For decades, scientists have argued whether the Moon had a strong or weak magnetic field during its early history (3.5 - 4 billion years ago). Now a new analysis – published today in Nature Geoscience – shows that both sides of the debate are effectively correct. Using samples from the Apollo missions, the researcher

Feb 26

Imperial: First-in-class drug candidate for multiple myeloma shows promise in Phase 1 trial

A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients. Multiple myeloma (MM) is a cancer of plasma cells, accounting for about 200,000 annual new cases globally. Despite recent therapeutic advances, MM remains incurable and an area of substantial unmet medical need. Professor Guido Franzoso in Imperial College London’s Department of Immunology and I

Feb 23